Partial androgen insensitivity syndrome (PAIS) is a rare genetic disorder first described in the literature in the mid-20th century. This condition is caused by mutations in the AR gene encoding the androgen receptor, which results in its dysfunction. As a result of this process, the body cannot fully respond to androgen hormones such as testosterone, which is key to the development of sexual characteristics. The clinical picture of PAIS is diverse and can range from subtle to severe, depending on the degree of receptor insensitivity. Patients with complete insensitivity develop female sexual characteristics even in the presence of XY chromosomes, while those with partial insensitivity exhibit both male and female sexual characteristics. This disorder requires a complex and multifaceted approach to diagnosis and treatment.
History of the disease and interesting historical facts
Partial androgen insensitivity syndrome was first described in 1955 by American endocrinologist John S. Burritt. Since then, many studies have been conducted that have greatly expanded our understanding of this condition. It is interesting to note that many cases of androgen insensitivity were identified after genetic studies were conducted, as the clinical manifestations can vary. In the 1970s, intensive research into the genetic basis of PISS began, which led to the discovery of mutations in the AR gene. In the following years, various phenotypes of this syndrome were described, making it one of the most studied diseases in the field of genetic endocrinology.
Epidemiology
CHF is a rare disorder, with an estimated prevalence of 1 in 20,000 to 1 in 100,000 live births, depending on the population. According to several studies, most cases remain unrecognized, as many people with mild forms of the syndrome may not have obvious clinical signs. In most cases, the disorder is diagnosed during puberty or during testing for other reasons. The syndrome has been shown to occur in both males and females, although the presentation may vary significantly. Studies suggest that CHF may be underreported in populations where the predisposition to genetic disorders is low.
Genetic predisposition to this disease
The most common cause of partial androgen insensitivity syndrome is mutations in the AR gene, located on the X chromosome. This gene codes for the androgen receptor, which is responsible for the binding and action of androgens in the body. Research shows that more than 90% cases of partial androgen insensitivity syndrome are caused by different types of mutations, such as point mutations, deletions, or insertions in the AR gene. Classification of mutations may include:
- Receptors with partial function, resulting in an incomplete response to androgens;
- Complete impairment of receptor function, resulting in complete insensitivity to androgens;
- Specific mutations that result in changes in receptor conformation or stability.
Genetic testing plays a key role in confirming the diagnosis and understanding the severity of the condition.
Risk factors for the development of this disease
Partial androgen insensitivity syndrome is caused mainly by genetic factors, but certain risks that contribute to the development of this condition can also be identified:
- Heredity: presence of cases of androgen insensitivity in the family;
- XY karyotype in women with signs of insufficiency of male sexual characteristics.
- Age of parents at conception: Aging fathers may be associated with increased mutations.
Although environmental and lifestyle factors do not play a significant role in the pathogenesis of CHF, genetic aspects remain the main triggers for the development of the disease.
Diagnosis of this disease
Diagnosis of partial androgen insensitivity syndrome involves a multidisciplinary approach, which includes:
- History taking: examining symptoms, medical history, and family history.
- A clinical examination that identifies characteristics of sexual development.
- Laboratory tests: determination of levels of testosterone, dihydrotestosterone and other sex hormones.
- Genetic testing: AR gene sequencing to detect mutations.
- Ultrasound examination of the pelvic organs to assess the evolution of the genital organs.
Differential diagnosis is important to exclude other genetic and hormonal disorders such as Klinefelter syndrome, as well as other forms of androgen deficiency.
Treatment
Treatment for partial androgen insensitivity syndrome depends on the severity of the disease and includes:
- General treatment: observation of patients with mild forms of the syndrome without intervention.
- Pharmacological treatment: use of androgens when needed to stimulate growth and development.
- Surgical treatment: resection or correction of the external genitalia, if necessary to achieve an acceptable aesthetic result.
- Psychological support: working with psychologists and social workers to help with social acceptance.
It is important that the treatment approach is individualized, which requires the interaction of a multidisciplinary team of specialists.
List of medications used to treat this disease
The following groups of drugs can be used to treat partial androgen insensitivity syndrome:
- Testosterone: to correct hormonal levels, if appropriate;
- Estrogens: can be used in cases where replacement is needed.
- Androgen stimulants: used to increase the manifestation of secondary sexual characteristics.
Each treatment must be carefully thought out and individualized for the specific patient.
Disease monitoring
Monitoring of patients with partial androgen insensitivity syndrome includes:
- Regular monitoring of hormone levels to assess the effectiveness of treatment;
- Assessment of sexual development and general physical status;
- Discussion of psychological state and social acceptance;
- Prognosis: With early diagnosis and adequate treatment, most patients lead full lives.
Major complications may include problems with gender role adjustment and psychosocial consequences.
Age-related features of the disease
Partial androgen insensitivity syndrome can manifest itself at different age stages:
- Newborn period: often not determined.
- Childhood period: may be characterized by underdevelopment of the genitals.
- Puberty: atypical sexual characteristics begin to appear.
- Adulthood: Patients may require assistance with social and sexual relationships.
It is important to take into account age-related changes in hormonal levels and adaptation to the social environment.
Questions and Answers
- What is partial androgen insensitivity syndrome? It is a genetic disorder associated with mutations in the androgen receptor, which results in an abnormal response of the body to androgens.
- How is CHF diagnosed? Diagnosis includes clinical examination, laboratory tests of sex hormone levels, and genetic tests for mutations in the AR gene.
- How is this syndrome treated? Treatment may include hormone therapy, surgery, and psychological support.
- What is the prognosis for patients with this syndrome? Treatment and monitoring options allow most patients to lead full lives with minimal limitations.
- Does the syndrome affect life in adulthood? Yes, patients may experience difficulties in social relationships and will require psychosocial support.
